PSIVIDA PROVIDES UPDATE ON BRACHYSIL LIVER PROGRAM

Global bio-nanotech company pSivida Limited today announced that the scope of the BrachySil phase IIb clinical trial for inoperable primary liver cancer has expanded to encompass a roll-out to further clinical centers in new Asian territories. In addition to the five centers currently active in Singapore, and centers in Vietnam and Malaysia, new centers are being negotiated in the Philippines and Taiwan.
Genetic Engineering News